Saturday 18 Jan, 2025 03:17 PM
Site map | Locate Us | Login
   Supreme Petrochem Q3 PAT climbs 5% YoY to Rs 71 crore    5paisa Capital PAT rises 7% YoY to Rs 16-cr in Q3 FY25    ICICI Lombard Q3 PAT spurts 68% YoY to Rs 724 crore    Jio Financial PAT rises to Rs 295 cr in Q3 FY25    Gland Pharma gets EIR from USFDA for Pashamylaram facility    IDBI Bank shares surge on disinvestment update    Wipro Q3 PAT rises 5% QoQ to Rs 3,354 cr, declares interim dividend of Rs 6/sh    Tech Mahindra Q3 PAT slides 21% QoQ    SBI Life gains as PAT jumps 71% YoY to Rs 551-cr in Q3 FY25    SSWL declines as Q3 PAT slips 14% YoY to Rs 51 crore    Capital Infra Trust make muted debut    Swaraj Engines gains after Q3 PAT jumps 33% YoY    Sterling & Wilson Renewable Energy Ltd leads losers in 'A' group    Khaitan Chemicals posts PAT of Rs 12.55 crore in Q3 FY25    Malu Paper Mills Ltd leads losers in 'B' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Gland Pharma gets EIR from USFDA for Pashamylaram facility
18-Jan-25   10:50 Hrs IST

The Pashamylaram facility received an EIR, which indicates closure of the inspection, Gland Pharma said in a filing.

The USFDA inspected the facility between 25 July 2024 and 2 August 2024 for good manufacturing practices (GMP) and issued three Form 483 observations. These observations were procedural in nature.

Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24.

The scrip rose 0.10% to settle at Rs 1,678.95 on Friday, 18 January 2025.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 38281132
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd